Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Harvard Business School
Argus Health
Farmers Insurance
Fish and Richardson

Generated: December 13, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,612,208

« Back to Dashboard

Which drugs does patent 7,612,208 protect, and when does it expire?

Patent 7,612,208 protects LENVIMA and is included in one NDA.

This patent has thirty-nine patent family members in twenty-six countries.

Summary for Patent: 7,612,208

Title:Crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinoli- necarboxamide or the solvate of the salt and a process for preparing the same
Abstract: A crystal of a 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinoli- necarboxamide hydrochloride, hydrobromide, p-toluenesulfonate, sulfate, methanesulfonate or ethanesulfonate, or a solvate thereof.
Inventor(s): Matsushima; Tomohiro (Tsukuba, JP), Nakamura; Taiju (Kamisu, JP), Yoshizawa; Kazuhiro (Kamisu, JP), Kamada; Atsushi (Tsukuba, JP), Ayata; Yusuke (Kamisu, JP), Suzuki; Naoko (Ushiku, JP), Arimoto; Itaru (Tokyo, JP), Sakaguchi; Takahisa (Tsukuba, JP), Gotoda; Masaharu (Tsukuba, JP)
Assignee: Eisai R&D Management Co., Ltd. (Tokyo, JP)
Application Number:10/577,531
Patent Claim Types:
see list of patent claims
Compound; Process; Composition; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Eisai IncLENVIMAlenvatinib mesylateCAPSULE;ORAL206947-001Feb 13, 2015RXYesNo► Subscribe► Subscribe► SubscribeYY
Eisai IncLENVIMAlenvatinib mesylateCAPSULE;ORAL206947-002Feb 13, 2015RXYesYes► Subscribe► Subscribe► SubscribeYY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,612,208

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2003-430939Dec 25, 2003
PCT Information
PCT FiledDecember 22, 2004PCT Application Number:PCT/JP2004/019223
PCT Publication Date:July 14, 2005PCT Publication Number: WO2005/063713

International Patent Family for Patent: 7,612,208

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China101337931► Subscribe
China101337932► Subscribe
China101337933► Subscribe
European Patent Office1698623► SubscribePA2015039Lithuania► Subscribe
European Patent Office1698623► SubscribePA2015039,C1698623Lithuania► Subscribe
European Patent Office1698623► Subscribe261 5023-2015Slovakia► Subscribe
Cyprus1116312► Subscribe
Denmark1698623► Subscribe
European Patent Office2567955► Subscribe
Japan4648835► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Boehringer Ingelheim
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: